Active substances
Hydrochlorothiazide + Lisinopril
- SFDA 1
- US FDA 15
- Health Canada 12
- US price lines 3
- NHS prices 2
- WHO EML 1
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| ZESTORETIC 20 TAB | 20,12.5 mg,mg | Tablet · Oral use | 28 Blister | SAR 62.25 | NCE · Prescription | AstraZeneca | Withdrawn by MAH · Not Marketed |
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| ZESTORETIC | 12.5MG;20MG; 25MG;20MG; 12.5MG;10MG | tablet · oral | ALMATICA | Prescription | 20 Jul 1989 |
| LISINOPRIL AND HYDROCHLOROTHIAZIDE | 12.5MG;10MG; 12.5MG;20MG; 25MG;20MG | tablet · oral | SUN PHARM INDS LTD | Prescription | 1 Jul 2002 |
| LISINOPRIL AND HYDROCHLOROTHIAZIDE | 12.5MG;20MG; 25MG;20MG; 12.5MG;10MG | tablet · oral | WATSON LABS | Prescription | 1 Jul 2002 |
| LISINOPRIL AND HYDROCHLOROTHIAZIDE | 12.5MG;10MG; 12.5MG;20MG; 25MG;20MG | tablet · oral | PRINSTON INC | Prescription | 1 Jul 2002 |
| LISINOPRIL AND HYDROCHLOROTHIAZIDE | 12.5MG;10MG; 12.5MG;20MG; 25MG;20MG | tablet · oral | AIPING PHARM INC | Prescription | 1 Jul 2002 |
| LISINOPRIL AND HYDROCHLOROTHIAZIDE | 12.5MG;10MG; 12.5MG;20MG; 25MG;20MG | tablet · oral | COREPHARMA | Prescription | 5 Oct 2004 |
| LISINOPRIL AND HYDROCHLOROTHIAZIDE | 12.5MG;10MG; 12.5MG;20MG; 25MG;20MG | tablet · oral | AUROBINDO | Prescription | 14 Mar 2006 |
| LISINOPRIL AND HYDROCHLOROTHIAZIDE | 12.5MG;10MG; 12.5MG;20MG; 25MG;20MG | tablet · oral | LUPIN | Prescription | 27 Sep 2006 |
| LISINOPRIL AND HYDROCHLOROTHIAZIDE | 12.5MG;10MG; 12.5MG;20MG; 25MG;20MG | tablet · oral | INVAGEN PHARMS | Prescription | 23 May 2017 |
| PRINZIDE | 12.5MG;20MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; 25MG;20MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; 12.5MG;10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | tablet · oral | MERCK | Discontinued | 16 Feb 1989 |
| LISINOPRIL AND HYDROCHLOROTHIAZIDE | 12.5MG;10MG; 12.5MG;20MG; 25MG;20MG | tablet · oral | CHARTWELL RX | Discontinued | 1 Jul 2002 |
| LISINOPRIL AND HYDROCHLOROTHIAZIDE | 12.5MG;10MG; 12.5MG;20MG; 25MG;20MG | tablet · oral | TEVA | Discontinued | 1 Jul 2002 |
| LISINOPRIL AND HYDROCHLOROTHIAZIDE | 12.5MG;10MG; 12.5MG;20MG; 25MG;20MG | tablet · oral | EPIC PHARMA LLC | Discontinued | 1 Jul 2002 |
| LISINOPRIL AND HYDROCHLOROTHIAZIDE | 12.5MG;10MG; 12.5MG;20MG; 25MG;20MG | tablet · oral | PHARMOBEDIENT | Discontinued | 1 Jul 2002 |
| LISINOPRIL AND HYDROCHLOROTHIAZIDE | 12.5MG;10MG; 12.5MG;20MG; 25MG;20MG | tablet · oral | HIKMA INTL PHARMS | Discontinued | 8 Jul 2002 |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| LISINOPRIL/HCTZ (TYPE Z) | 02362945 | 10 MG; 12.5 MG | TABLET · ORAL | SANIS HEALTH INC |
| LISINOPRIL/HCTZ (TYPE Z) | 02362953 | 20 MG; 12.5 MG | TABLET · ORAL | SANIS HEALTH INC |
| LISINOPRIL/HCTZ (TYPE Z) | 02362961 | 20 MG; 25 MG | TABLET · ORAL | SANIS HEALTH INC |
| SANDOZ LISINOPRIL HCT | 02302365 | 10 MG; 12.5 MG | TABLET · ORAL | SANDOZ CANADA INCORPORATED |
| SANDOZ LISINOPRIL HCT | 02302373 | 20 MG; 12.5 MG | TABLET · ORAL | SANDOZ CANADA INCORPORATED |
| SANDOZ LISINOPRIL HCT | 02302381 | 25 MG; 20 MG | TABLET · ORAL | SANDOZ CANADA INCORPORATED |
| TEVA-LISINOPRIL/HCTZ (TYPE Z) | 02301768 | 12.5 MG; 10 MG | TABLET · ORAL | TEVA CANADA LIMITED |
| TEVA-LISINOPRIL/HCTZ (TYPE Z) | 02301776 | 20 MG; 12.5 MG | TABLET · ORAL | TEVA CANADA LIMITED |
| TEVA-LISINOPRIL/HCTZ (TYPE Z) | 02301784 | 25 MG; 20 MG | TABLET · ORAL | TEVA CANADA LIMITED |
| ZESTORETIC | 02045729 | 20 MG; 25 MG | TABLET · ORAL | SEARCHLIGHT PHARMA INC |
| ZESTORETIC | 02045737 | 20 MG; 12.5 MG | TABLET · ORAL | SEARCHLIGHT PHARMA INC |
| ZESTORETIC | 02103729 | 10 MG; 12.5 MG | TABLET · ORAL | SEARCHLIGHT PHARMA INC |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | LISINOPRIL-HYDROCHLOROTHIAZIDE 10-12.5 MG TAB | $0.02934 | per EA | 23 Sep 2026 |
| US NADAC | LISINOPRIL-HYDROCHLOROTHIAZIDE 20-12.5 MG TAB | $0.03612 | per EA | 23 Sep 2026 |
| US NADAC | LISINOPRIL-HYDROCHLOROTHIAZIDE 20-25 MG TAB | $0.04084 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Lisinopril 10mg / Hydrochlorothiazide 12.5mg tablets | £8.71 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Lisinopril 20mg / Hydrochlorothiazide 12.5mg tablets | £9.34 | 28 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 12.3. Antihypertensive medicines · core
Essential hypertension
Oral > Solid: 10 mg + 12.5 mg; 20 mg + 12.5 mg; 20 mg + 25 mg
Components
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.